Larimar Therapeutics price target raised to $12 from $11 at Wedbush

2 hours ago 1

TipRanks

Wed, March 4, 2026 astatine 7:50 AM CST 1 min read

Wedbush raised the firm’s price target connected Larimar Therapeutics (LRMR) to $12 from $11 and keeps an Outperform standing connected the shares. The steadfast notes that past week, the institution completed an upsized $100M offering pursuing receipt of Breakthrough Therapy designation for nomlabofusp successful Friedreich’s ataxia. After incorporating the raise, Wedbush is besides expanding its Q4 spending to necktie with year-end 2025 currency $137M. While the steadfast acknowledges caller FDA decisions person been a root of interest for investors, Wedbush is encouraged Larimar continues to clasp an progressive dialog with the agency.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected LRMR:

Disclaimer & DisclosureReport an Issue

Larimar Therapeutics Announces Upsized Public Equity Offering
Larimar Therapeutics 20M stock Spot Secondary priced astatine $5.00
Larimar Therapeutics $75M Spot Secondary terms scope $4.75-$5.25
Larimar Therapeutics terms people raised to $14 from $12 astatine Citi
Midday Fly By: Home Depot reports Q4 beat, AMD and Meta grow partnership

Read Entire Article